Drug Trial Radar · NCT02263547
Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride
Last checked: Nov 20, 2026Latest source record: Apr 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
14
Actual
Start
Mar 2015
Primary completion
Jun 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- Derrick Scott RobertsonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Genzyme, a Sanofi Company; University of South Florida
- First posted
- Oct 13, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective To determine if colestipol hydrochloride tablets can accelerate the elimination of teriflunomide. Teriflunomide will be administered for 14 days followed by colestipol dosing of 11 days. Total duration of the study is 40 days. Secondary Objectives To collect information on the pattern of side effects with use of colestipol hydrochloride after teriflunomide administration and to determine the best duration of therapy needed for adequate elimination
Conditions
- Teriflunomide Elimination
- Healthy Volunteers
Interventions
teriflunomideDrug
ColestipolDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome Measures: Teriflunomide Concentrations at Day 28Time frame: 28 days after the start in the study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
USF Carol and Frank Morsani Center for Advanced Healthcare
Tampa, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.